Efficacy and safety of adjuvant targeted immunotherapy for hepatocellular carcinoma with high recurrence risks after hepatectomy

Figure 1 Schematic description of the study design. ATG: Adjuvant therapy group; PSM: Propensity score matching; SG: Surgery-alone group.

Figure 2 Adjuvant therapy regimen details. Cam: Camrelizumab; Pem: Pembrolizumab; Tis: Tislelizumab; Tor: Toripalimab; Anl: Anlotinib; Apa: Apatinib; Len: Lenvatinib; Sor: Sorafenib.

Figure 3 Kaplan-Meier survival curves before and after propensity score matching. A and B: Recurrence-free survival curves comparing the adjuvant therapy group vs the surgery-only group before (A) and after 1:1 propensity score matching (B); C and D: Overall survival curves for the same groups before (C) and after matching (D). P values were calculated using the log-rank test.

Figure 4 Comparison of recurrence-free survival among adjuvant therapy subgroups. Kaplan-Meier curves for recurrence-free survival were compared between different adjuvant therapy regimens within the cohort. A: Targeted therapy group vs immunotherapy group (log-rank P = 0.26); B: Targeted therapy group vs combination therapy group (log-rank P = 0.57); C: Immunotherapy group vs combination therapy group (log-rank P = 0.49).